Navigation Links
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Date:9/2/2008

NEW YORK, Sept. 3 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. today announced results from two global Phase III studies of aclidinium bromide, a novel long-acting inhaled anticholinergic for the treatment of patients with chronic obstructive pulmonary disease (COPD). In both the ACCLAIM/COPD I&II (AClidinium CLinical Trial Assessing Efficacy and Safety In Moderate to Severe COPD Patients) studies, once-daily aclidinium bromide showed a statistically significant difference vs. placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in moderate to severe COPD patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

In both studies aclidinium therapy demonstrated a significant difference vs placebo in trough FEV1 at 12 weeks (p-value <0.001) and 28 weeks (p-value <0.001). The effect of aclidinium compared to placebo in trough FEV1 was maintained over one year (p-value <0.001). The improvement in the trough FEV1, at weeks 12 and 28, of aclidinium arms compared to placebo was in the range of 60 to 70 mL in both trials. The change from baseline in peak FEV1 observed after dosing aclidinium compared to placebo at 12 and 28 weeks was between 154 and 177 mL (p-value <0.0001), with a median time to peak of 2 hours.

"The studies confirm the bronchodilatory effect of aclidinium at the dose tested, although the magnitude was lower than seen in previous studies. We are working actively with Forest and members of the ACCLAIM/COPD Steering Committee to fully understand these findings to determine the best way forward including the extent of the
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BEDFORD, Mass., July 30, 2014  Hologic, Inc. (NASDAQ: ... the third fiscal quarter ended June 28, 2014. ... , Revenues increased 1.0% to $632.6 million, reflecting operational ... 0.5%, compared to the same period in the prior ... four business segments. , Breast Health revenues grew 3.5%. ...
(Date:7/30/2014)... , July 30, 2014 The ... Care Pharmacy (AMCP) last evening expressed support for ... the Joint Commission of Pharmacy Practitioners (JCPP).  As ... organizations over a two-year period to develop a ... pharmacists.  "Pharmacists are fast becoming ...
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3
... 09, 2007 /PRNewswire-FirstCall/ --,Catalyst Pharmaceutical Partners, Inc. ... bioequivalence study demonstrating,that CPP-109 (Catalyst's Vigabatrin Tablets) ... version of vigabatrin marketed,in Europe by Sanofi ... linking CPP-109 to the extensive body of ...
... N.J. and BRISTOL, Tenn., May 09, 2007,/PRNewswire-FirstCall/ ... today announced plans to present the results,from ... with erectile,dysfunction (ED). The presenters are Jed ... NYU School of Medicine;,Stanley E. Althof, PhD, ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 4Palatin Technologies and King Pharmaceuticals Announce Plan To,Present Results of Bremelanotide Phase 2b Studies in Men With,Erectile Dysfunction 2Palatin Technologies and King Pharmaceuticals Announce Plan To,Present Results of Bremelanotide Phase 2b Studies in Men With,Erectile Dysfunction 3Palatin Technologies and King Pharmaceuticals Announce Plan To,Present Results of Bremelanotide Phase 2b Studies in Men With,Erectile Dysfunction 4
(Date:7/30/2014)... July 30, 2014 Ticket Down is ... Tickets in Ann Arbor, MI on Saturday, August 2nd. ... international football will be competing on American soil on Aug. 2 ... in Ann Arbor, Mich. The home of the University of Michigan ... the most prestigious in all of American sports and has also ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July ... their preschooler shed excess pounds may want to team up ... joined them in a supervised behavioral modification program gained less ... child-only program (an average difference of about four pounds over ... pounds over two years, according to the study. "In ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
Breaking Medicine News(10 mins):Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 2Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 4Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... , ... recent report in the medical journal Osteoporosis International found that women taking AdvaCAL® calcium ... 1977 and 2008. The 32 studies involved 3,169 postmenopausal women, 79 skeletal measures and ... ...
... ... settled in Dubai, received the very prestigious ,HIND RATTAN AWARD, this week ... was presented at a ceremony in connection with the yearly International Congress ... Industries and Public Enterprises, Government of India. Dr. Mehta was awarded for ...
... ... Logan Consulting, a Chicago, IL based management consulting and technology firm, ... Chicago, IL based Microsoft Gold Certified Partner, effective January 1, 2010. ... services, serving clients across North America, Europe and Asia since 1992. ...
... ... connectors, is utilizing their nano-connector Bi-lobes® to help handle difficult signal routing and ... ... the leading manufacturer of miniature high-rel connectors, is utilizing their nano-connector Bi-lobes® to ...
... ... Vemma Nutrition Company launches Vemma THIRST, ... other sports drinks, Vemma THIRST goes beyond hydration by delivering ... while replenishing the body with necessary electrolytes, specialized carbohydrates and ...
... , Majority of Mississippi voters support e-tracking ... The following is a statement by Linda ... Association (CHPA): , "Today, the Mississippi House of Representatives ... becomes law, will greatly limit how cold and allergy sufferers access ...
Cached Medicine News:Health News:Report: AdvaCALCalcium Builds Bone Best 2Health News:Dr. Mahaveer Mehta, A Well Known Dermatologist from Dubai, Receives Prestigious 'Hind Rattan Award' 2Health News:Dr. Mahaveer Mehta, A Well Known Dermatologist from Dubai, Receives Prestigious 'Hind Rattan Award' 3Health News:Logan Consulting Merges with Cornerstone Solutions 2Health News:Logan Consulting Merges with Cornerstone Solutions 3Health News:Omnetics Nano-to-Flex Connectors Solve Big Problems in Small Spaces 2Health News:Vemma Revolutionizes the Sports Drink Market With Vemma THIRST&#8482; 2Health News:Statement from the Consumer Healthcare Products Association on Mississippi Bill that Seeks to Make Cold, Allergy Medicines Containing Pseudoephedrine Prescription-Only 2Health News:Statement from the Consumer Healthcare Products Association on Mississippi Bill that Seeks to Make Cold, Allergy Medicines Containing Pseudoephedrine Prescription-Only 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: